☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New GLP analogue launched

Liraglutide (Victoza®) has been launched for the treatment of patients with type 2 diabetes. This new drug is a glucagon-like peptide (GLP-1) analogue and is in the same class as exenatide (Byetta®).

There are slight differences between the two products in terms of the product licence. Exenatide is licensed for combination use with metformin and/or a sulphonylurea in patient not achieving adequate glycaemic control. Liraglutide is licensed in these same combinations and also in combination with metformin and a glitazone.

Exenatide has been considered in the most recent NICE Diabetes guidance but specific advice from NICE for liraglutide is not due until June 2010.

Action: Clinicians should be aware of this new drug, the licensed indications and status of the current NICE guidance.

Share 'New GLP analogue launched' by emailShare 'New GLP analogue launched' on FacebookShare 'New GLP analogue launched' on TwitterShare 'New GLP analogue launched' on LinkedInShare 'New GLP analogue launched' on reddit


No Comments to “New GLP analogue launched”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.